Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 2/20 | 0.33 |
| ▸ | CD38 | P28907 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.32 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.32 |
| ▸ | IDH1 | O75874 | 1/20 | 0.32 |
| ▸ | CTPS1 | P17812 | 1/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22758543 | 0.87 | NPSR1 (0.33) | PDE4BCYP2C19CTPS1 | |
| SCHEMBL21392084 | 0.83 | CYP3A4 (0.41) | PDE4BCYP2C19CTPS1 | |
| SCHEMBL22758542 | 0.82 | CTPS1 (0.33) | PDE4BCTPS1 | |
| SCHEMBL22762471 | 0.81 | L3MBTL1 (0.34) | PDE4BCYP2C19 | |
| SCHEMBL22762263 | 0.80 | CTPS1 (0.48) | CTPS1 | |
| SCHEMBL24849318 | 0.80 | FFAR4 (0.34) | PDE4BCD38CYP2D6CYP2B6CYP2C19 | |
| SCHEMBL24849581 | 0.77 | MMP2 (0.33) | PDE4BCYP2C19 | |
| SCHEMBL21373839 | 0.71 | CTPS1 (0.49) | CTPS1 | |
| SCHEMBL21373841 | 0.69 | TRPV1 (0.36) | — | |
| SCHEMBL21373873 | 0.69 | CTPS1 (0.50) | CTPS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230020663-A1 | SULFONAMIDE INHIBITORS AS CTPS1 INHIBITORS | STEP PHARMA S.A.S. (FR) | 2023-01-19 | — | — | US | disclosed |
| US-20230002352-A1 | SULFONAMIDE DERIVATIVES AS CTPS1 INHIBITORS | STEP PHARMA S.A.S. (FR) | 2023-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230020663-A1 | SULFONAMIDE INHIBITORS AS CTPS1 INHIBITORS | CTPS1, CTPS2, TYMS | PDE4B 2860/4885CD38 780/4885CYP2D6 2116/4885 |
| US-20230002352-A1 | SULFONAMIDE DERIVATIVES AS CTPS1 INHIBITORS | CTPS1, CTPS2, TYMS | PDE4B 2745/4885CD38 882/4885CYP2D6 1852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.